Ricardo Correia, Taja Zotler, Francisco Ferraz, Bárbara Fernandes, Miguel Graça, Gorben P. Pijlman, Paula M. Alves, António Roldão
{"title":"Continuous Production of Influenza VLPs Using IC‐BEVS and Multi‐Stage Bioreactors","authors":"Ricardo Correia, Taja Zotler, Francisco Ferraz, Bárbara Fernandes, Miguel Graça, Gorben P. Pijlman, Paula M. Alves, António Roldão","doi":"10.1002/bit.28925","DOIUrl":null,"url":null,"abstract":"The insect cell‐baculovirus expression vector system (IC‐BEVS) has been an asset to produce biologics for over 30 years. With the current trend in biotechnology shifting toward process intensification and integration, developing intensified processes such as continuous production is crucial to hold this platform as a suitable alternative to others. However, the implementation of continuous production has been hindered by the lytic nature of this expression system and the process‐detrimental virus passage effect. In this study, we implemented a multi‐stage bioreactor setup for continuous production of influenza hemagglutinin‐displaying virus‐like particles (HA‐VLPs) using IC‐BEVS. A setup consisting of one Cell Growth Bioreactor simultaneously feeding non‐infected insect cells to three parallel Production Bioreactors operated at different residence times (RT) (18, 36, and 54 h) was implemented; Production Bioreactors were continuously harvested. Two insect cell lines (neutral pH–adapted High Five and <jats:italic>Sf</jats:italic>9) and two recombinant baculovirus (rBAC) constructs (one that originates from a bacmid, rBAC<jats:sub>bacmid</jats:sub>, and another of non‐bacteria origin, rBAC<jats:sub>flashbac</jats:sub>) were tested. Combining rBAC<jats:sub>flashbac</jats:sub> with <jats:italic>Sf</jats:italic>9 cells was the most efficient approach, allowing consistent HA‐VLPs titers (34 ± 14 HA titer/mL) and rBAC titers (10<jats:sup>8</jats:sup>–10<jats:sup>9</jats:sup> pfu/mL) throughout the period of continuous operation (20 days). Cell growth kinetics and viability varied across RT, and higher RT was associated with increased expression of HA‐VLPs, independent of the cell line and rBAC used; RT of 54 h allowed to maximize titers. The presence of particles resembling HA‐VLPs was confirmed by transmission electron microscopy throughout the continuous operation. This work showcases the implementation of a process for continuous production of a promising class of biotherapeutics (i.e., VLPs), and paves the way for establishing continuous, integrated setups using the IC‐BEVS expression system.","PeriodicalId":9168,"journal":{"name":"Biotechnology and Bioengineering","volume":"56 1","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology and Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/bit.28925","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The insect cell‐baculovirus expression vector system (IC‐BEVS) has been an asset to produce biologics for over 30 years. With the current trend in biotechnology shifting toward process intensification and integration, developing intensified processes such as continuous production is crucial to hold this platform as a suitable alternative to others. However, the implementation of continuous production has been hindered by the lytic nature of this expression system and the process‐detrimental virus passage effect. In this study, we implemented a multi‐stage bioreactor setup for continuous production of influenza hemagglutinin‐displaying virus‐like particles (HA‐VLPs) using IC‐BEVS. A setup consisting of one Cell Growth Bioreactor simultaneously feeding non‐infected insect cells to three parallel Production Bioreactors operated at different residence times (RT) (18, 36, and 54 h) was implemented; Production Bioreactors were continuously harvested. Two insect cell lines (neutral pH–adapted High Five and Sf9) and two recombinant baculovirus (rBAC) constructs (one that originates from a bacmid, rBACbacmid, and another of non‐bacteria origin, rBACflashbac) were tested. Combining rBACflashbac with Sf9 cells was the most efficient approach, allowing consistent HA‐VLPs titers (34 ± 14 HA titer/mL) and rBAC titers (108–109 pfu/mL) throughout the period of continuous operation (20 days). Cell growth kinetics and viability varied across RT, and higher RT was associated with increased expression of HA‐VLPs, independent of the cell line and rBAC used; RT of 54 h allowed to maximize titers. The presence of particles resembling HA‐VLPs was confirmed by transmission electron microscopy throughout the continuous operation. This work showcases the implementation of a process for continuous production of a promising class of biotherapeutics (i.e., VLPs), and paves the way for establishing continuous, integrated setups using the IC‐BEVS expression system.
期刊介绍:
Biotechnology & Bioengineering publishes Perspectives, Articles, Reviews, Mini-Reviews, and Communications to the Editor that embrace all aspects of biotechnology. These include:
-Enzyme systems and their applications, including enzyme reactors, purification, and applied aspects of protein engineering
-Animal-cell biotechnology, including media development
-Applied aspects of cellular physiology, metabolism, and energetics
-Biocatalysis and applied enzymology, including enzyme reactors, protein engineering, and nanobiotechnology
-Biothermodynamics
-Biofuels, including biomass and renewable resource engineering
-Biomaterials, including delivery systems and materials for tissue engineering
-Bioprocess engineering, including kinetics and modeling of biological systems, transport phenomena in bioreactors, bioreactor design, monitoring, and control
-Biosensors and instrumentation
-Computational and systems biology, including bioinformatics and genomic/proteomic studies
-Environmental biotechnology, including biofilms, algal systems, and bioremediation
-Metabolic and cellular engineering
-Plant-cell biotechnology
-Spectroscopic and other analytical techniques for biotechnological applications
-Synthetic biology
-Tissue engineering, stem-cell bioengineering, regenerative medicine, gene therapy and delivery systems
The editors will consider papers for publication based on novelty, their immediate or future impact on biotechnological processes, and their contribution to the advancement of biochemical engineering science. Submission of papers dealing with routine aspects of bioprocessing, description of established equipment, and routine applications of established methodologies (e.g., control strategies, modeling, experimental methods) is discouraged. Theoretical papers will be judged based on the novelty of the approach and their potential impact, or on their novel capability to predict and elucidate experimental observations.